Tianfeng Securities' pharmaceutical team reiterated its positive view on Nanomicro Tech after the company's Q3 2026 pre-announcement showed revenue up 32% year-over-year for the first three quarters and net profit up 102%, with core microsphere product sales growing over 40%.
Tianfeng maintains a bullish stance on Nanomicro Tech, citing high growth in Q3 results and strong demand from GLP-1 and oligonucleotide businesses.
Free preview — more China A-share & HK research · About Us · Legal & Privacy